Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc{gamma}RIIa and CXCR1/2.
Antiendothelial cell antibodies (AECAs) are commonly detectable in diseases associated with vascular injury, including systemic lupus erythematosus (SLE), systemic sclerosis, Takayasu arteritis, Wegener granulomatosis, Behçet syndrome, and transplant arteriosclerosis. Here, we explore the hypothesis that these antibodies might augment polymorphonuclear leukocyte (PMN) adhesion to endothelium in inflammation. Initially, we established that a mouse IgG mAb bound to endothelial cells (ECs) significantly increased PMN adhesion to cytokine-stimulated endothelium in an FcgammaRIIa-dependent manner. Neutralizing antibodies, and adenoviral transduction of resting ECs, demonstrated that the combination of E-selectin, CXCR1/2, and beta(2) integrins is both necessary and sufficient for this process. We observed an identical mechanism using AECA IgG isolated directly from patients with SLE. Assembled immune complexes also enhanced PMN adhesion to endothelium, but, in contrast to adhesion because of AECAs, this process did not require CXCR1/2, was not inhibited by pertussis toxin, and was FcgammaRIIIb rather than FcgammaRIIa dependent. These data are the first to demonstrate separate nonredundant FcgammaRIIa and FcgammaRIIIb-mediated mechanisms by which EC-bound monomeric IgG and assembled immune complexes amplify leukocyte adhesion under dynamic conditions. Furthermore, the observation that FcgammaRIIa and CXCR1/2 cooperate to enhance PMN recruitment in the presence of AECAs suggests a mechanism whereby AECAs may augment tissue injury during inflammatory responses.
Florey
Oliver J
OJ
British Heart Foundation, Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK.
Johns
Michael
M
Esho
Olubukola O
OO
Mason
Justin C
JC
Haskard
Dorian O
DO
D000818:Animals; D015703:Antigens, CD / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D002448:Cell Adhesion / Q000187:drug effects / Q000276:immunology; D002461:Cell Line, Transformed; D018920:Coculture Techniques; D004730:Endothelium, Vascular / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D007962:Leukocytes / Q000276:immunology* / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000473:pathology; D051379:Mice; D037342:Pertussis Toxin / Q000494:pharmacology; D017452:Receptors, IgG / Q000276:immunology*; D023062:Receptors, Interleukin-8A / Q000276:immunology*; D023063:Receptors, Interleukin-8B / Q000276:immunology*
D015703:Antigens, CD; D001323:Autoantibodies; C499173:FCGR2B protein, human; C080568:Fc gamma receptor IIA; D017452:Receptors, IgG; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B; D037342:Pertussis Toxin